Market capitalization | $689.75m |
Enterprise Value | $568.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 84.38 |
P/S ratio (TTM) P/S ratio | 102.34 |
P/B ratio (TTM) P/B ratio | 6.45 |
Revenue growth (TTM) Revenue growth | -69.69% |
Revenue (TTM) Revenue | $6.74m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
5 Analysts have issued a Arbutus Biopharma Corporation forecast:
5 Analysts have issued a Arbutus Biopharma Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6.74 6.74 |
70%
70%
|
|
Gross Profit | 5.34 5.34 |
74%
74%
|
|
EBITDA | -77 -77 |
0%
0%
|
EBIT (Operating Income) EBIT | -79 -79 |
0%
0%
|
Net Profit | -77 -77 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
Head office | Canada |
CEO | Michael McElhaugh |
Employees | 73 |
Founded | 2005 |
Website | www.arbutusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.